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Radiotherapy for iris metastasis from esophageal carcinoma:
A series of three cases
Chandana Das, Carol L. Shields
The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA

Background: Description of three cases of metastatic
esophageal carcinoma to the iris and focus on
management strategies.
Methods: A 48‑year‑old man (Case 1) with previously
treated stage IV esophageal carcinoma presented with
blurred vision in the left eye (OS) for 3 weeks. Initial
fine needle aspiration biopsy (FNAB) was negative for
malignant cells, so incisional biopsy was performed
and confirmed metastatic carcinoma. A 53‑year‑old
man (Case 2) with previously treated stage III
esophageal cancer experienced 2 months of pain and
1 month of blurred vision OS. Documented tumor
growth suggested esophageal carcinoma metastasis.
A 65‑year‑old man (Case 3) with previously treated
stage IV esophageal carcinoma developed hyphema in
the right eye (OD), and FNAB confirmed metastatic
carcinoma.

Introduction
Metastatic cancer to the eye can arise from several systemic sites
and is typically found within the uvea. Shields et al. evaluated
520 eyes with uveal metastatic foci and found the most common
primary sites to include cancer of the breast (47%), lung (21%),
and gastrointestinal (GI) tract (4%).[1] Less commonly, uveal
metastases originated from primary cancers of the kidney, skin,
and prostate at 2% each.[1] Esophageal metastasis represented
only 0.2% of the entire group (1 patient of the 420 patient
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Results: Case 1 was treated with external beam
radiotherapy (EBRT), delivered over 16 days which
resulted in complete tumor regression. Case 2 received
stereotactic body radiotherapy (SBRT) over 21 days
leading to complete tumor regression. Case 3 was
treated with plaque radiotherapy over 4 days, resulting
in complete tumor regression.
Conclusions: In all three cases, radiotherapy was
employed, and enucleation was avoided. Plaque
radiotherapy achieved tumor control in a shorter
period of time (4 days) compared to EBRT (16 days)
or SBRT (21 days). Knowing the short life expectancy
of these patients, plaque radiotherapy appears most
favorable.
Keywords: Esophageal carcinoma, eye, iris, metastasis,
plaque radiotherapy, radiotherapy

sample).[1] However, the incidence of esophageal and gastric
cardia adenocarcinoma has been rising at an average rate of 1.7%
per year between 1999 and 2008, representing cancer that should
be recognized.[2]
Metastatic tumors to the eye classically present in the choroid (88%)
and less often in the iris (9%) or ciliary body (2%).[1] Management
of uveal metastasis involves systemic chemotherapy, external
radiotherapy, or focal plaque radiotherapy. Plaque radiotherapy
is a form of brachytherapy in which a localized radiotherapy
dose can be achieved over a select portion of the eye using a
curvilinear applicator over a short period of time. It has been
shown to be effective in the treatment of choroidal melanoma,
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choroidal metastases, iris melanoma, and other tumors. Herein,
we illustrate three patients with esophageal carcinoma metastatic
to the iris treated with external beam radiotherapy (EBRT),
stereotactic body radiotherapy (SBRT), and plaque radiotherapy.
One of the benefits of plaque radiotherapy is the rapid delivery
of focal radiotherapy to a select site in the eye. The three patients
described survived a mean of 10 months from the time of iris
metastasis detection and plaque radiotherapy achieved tumor
control with 4 days of treatment (1% of the remaining lifetime),
whereas EBRT (16 days) and SBRT (21 days), occupied 5% and
7% of their remaining days, respectively.

Case Reports
Case 1
A 48‑year‑old white man presented with 3 weeks of blurred
vision in the left eye (OS) and history of biopsy proven stage
IV esophageal adenocarcinoma with metastases to the left
cervical lymph nodes, treated with EBRT and chemotherapy. On
examination, visual acuity was 20/20 in the right eye (OD) and
20/30 OS. Intraocular pressure (IOP) was normal. His left eye had
an iris stromal mass from 11:00 to 4:00 with ill‑defined margins
measuring 6 mm × 4 mm × 1 mm [Figure 1a and b]. The fundus
was normal in both eyes (OU). There were no active systemic
metastases at this point. A fine needle aspiration biopsy (FNAB)
of the lesion was negative for malignant cells. The patient was

followed with observation and returned 3 months later with
tumor growth, now encompassing the iris from 8:00 to 4:30, with
20/200 vision OS and IOP of 52 mm Hg OS. An incisional biopsy
revealed mucous secreting adenocarcinoma metastatic to the iris.
This eye was treated with an EBRT dose of 3000 cGy over 16 days.
Following treatment, visual acuity was 20/20 OD and 20/25 OS,
and his IOP had improved to 13 mm Hg OD and 16 mm Hg OS.
He later developed cataract with visual acuity of 20/400 OS and
died 13 months after his first visit [Table 1].

Case 2
A 53‑year‑old white man presented with 2 months of pain and
blurred vision. It was suspected elsewhere to be uveitis, but later,
a tumor was discovered. He gave a history of stage III esophageal
carcinoma with regional lymph node involvement, treated with
total esophagectomy and chemotherapy. On examination, visual
acuity was 20/20 OD and 20/100 OS with normal IOP of 10 mmHg
OD and 15 mmHg OS. The right eye was normal. In the left eye,
there was diffuse iris infiltration from 12:00 to 6:00 measuring
12 mm × 5 mm × 2.7 mm, with angle involvement at 5:00 and 7:00
and infiltration of the anterior lens capsule [Figure 1c and d]. In
addition, there was cystoid macular edema OS. Following 2 weeks
with documented growth, treatment with SBRT using a dose
of 3500 centigray in 14 fractions over 21 days was provided.[3]
Following treatment, tumor regression was documented.[3] The
patient died 12 months later [Table 1].

Case 3

a

b

c

d

A 65‑year‑old white man was found to have hyphema and a
tumor OD. His history was significant for biopsy‑proven stage
IV adenocarcinoma with metastases to the left supraclavicular
lymph node and bone, treated with chemotherapy. On
examination, visual acuity was 20/40 OD and 20/20 OS.
IOP was 31 mmHg OD and 18 mmHg OS. The left eye was
normal. The right eye had a multinodular iris mass measuring
4 mm × 3 mm × 2 mm [Figure 2a] with intrinsic vessels and
gonioscopic evidence of hyphema with tumor seeds, confirmed
on anterior segment optical coherence tomography [Figure 2b].
FNAB revealed poorly differentiated metastatic carcinoma.
A radioactive plaque using Iodine‑125 was placed over the tumor,
delivering 3500 centigray to the apex of the tumor over 4 days
and achieving complete tumor regression [Figure 2c and d] The
patient died 5 months after his first visit [Table 1].

Figure 1: Iris metastasis from esophageal carcinoma. (a) (Case 1) Ill-defined iris
metastasis within the iris stroma (arrows) causing iris thickening from 11:00 to 3:00.
(b) (Case 1) Slit beam highlights the region of iris thickening and irregular surface.
(c) (Case 2) Ill-defined iris metastasis (arrows) with a foamy appearance on the iris
surface from 12:00 to 4:00. (d) (Case 2) Anterior segment optical coherence tomography
shows the mass (arrow) on the iris surface

Discussion
The incidence of esophageal and gastric cardia adenocarcinoma
has increased sevenfold from 1973 to 2006, from 3.6 to 25.6 cases

Table 1: Summary of clinical features in each case of esophageal carcinoma metastasis to the iris and
managed with radiotherapy
Case

Age

Gender

Race

Number 1
Number 2
Number 3

48
53
65

Male
Male
Male

Caucasian
Caucasian
Caucasian

94

Systemic
cancer
Esophageal
Esophageal
Esophageal

Interval cancer to iris
metastasis (months)
12
14
9

Treatment of iris metastasis
External beam radiotherapy
Stereotactic radiotherapy
Plaque radiotherapy

Interval iris metastasis
to death (months)
13
12
5
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source of metastasis in 19 (4%) eyes.[1] In an analysis of 40 cases
of iris metastasis, only one case was from esophageal carcinoma,
highlighting the rarity of this finding.[6] However, there have been
case reports of esophageal adenocarcinoma metastasis to the iris
as the presenting manifestation of esophageal adenocarcinoma.[7]
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c
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d

Figure 2: Iris metastasis from esophageal carcinoma treated with plaque radiotherapy.
(a) (Case 3) Ill-defined iris metastasis extending from 12:00 to 8:00 with posterior
synechia at the site of a nodule at the 1:00 meridian. (b) (Case 3) Anterior segment
optical coherence tomography shows the mass as a nodule at the pupillary margin
(arrow). (c) (Case 3) Following plaque radiotherapy, the tumor has regressed to a flat
scar with persistent posterior synechia. (d) (Case 3) Following plaque radiotherapy,
anterior segment optical coherence tomography demonstrates flattened iris without a
mass (arrow)

per million according to Carr et al.[2] There are several reasons
for this alarming rise, including gastroesophageal reflux
disease (GERD), obesity, tobacco use, and low dietary intake
of fruits and vegetables.[4] Chronic inflammation (esophagitis)
resulting from GERD leads to the development of Barrett’s
esophagus, which is metaplasia of native squamous epithelium to
intestinal‑like columnar epithelium following chronic exposure
to gastric acid. This can culminate in cellular dysplasia and
invasive esophageal adenocarcinoma.[4] Obesity contributes by
increasing intra‑abdominal pressure, intensifying already existing
GERD, and increasing levels of adiponectin and insulin‑like
growth factors which modulate cellular proliferation and
apoptosis.[2] Obesity also contributes to the increased levels of
proinflammatory adipocytokines.[4] Multiple studies have linked
current or past tobacco use to the development of esophageal
adenocarcinoma.[2] Finally, diets high in carbohydrates and
saturated fats with a concurrent decrease in fruits and vegetables
may lead to increased insulin resistance and higher levels of
insulin‑like growth factors, contributing to carcinogenesis.[2]
The treatment of esophageal carcinoma depends on tumor
invasion and includes adjuvant chemoradiotherapy following
surgical resection through the transhiatal, transthoracic, or
endoscopy routes.[4] Prognosis depends on tumor stage with 5‑year
survival at 82% for stage 0 (high‑grade dysplasia, G1); 64–77% for
stage I (T1‑2, N0, M0, G1‑3); 40–50% for stage II (T1‑3, N0‑1, M0,
G3‑any); and 15–25% for stage III (T1‑4b, N0‑any, M0, G any).[5]
Five‑year survival can be assumed to be <15% in patients with
stage IV (T any, N any, M1, G any) esophageal adenocarcinoma.
Esophageal carcinoma rarely metastasizes to the eye, and
generally to the choroid when it does. In a large analysis of 520
eyes with metastatic disease, cancers of the GI tract were the
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Plaque radiotherapy is a form of brachytherapy using an applicator
with radioactive material lined by protective, radiation‑safe
gold. This technology has been used for several decades to
treat choroidal melanoma and more recently to treat choroidal
metastasis.[8] Plaque radiotherapy was also adapted to treat iris
melanoma, particularly those that are nonresectable.[9]
In 1995, Shields et al. reported the use of plaque radiotherapy for iris
metastasis in four cases.[10] All four cases demonstrated complete
regression without recurrence.[10] Subsequent reports on the use
of plaque radiotherapy for iris malignancy, particularly melanoma,
have disclosed the safety and efficacy of this approach.[11]
In our series of three cases of iris metastasis from esophageal
carcinoma, each patient received radiotherapy in different forms.
Case 1 was treated with EBRT over 16 days, and Case 2 received
SBRT over 21 days, both with complete tumor regression. The
therapy occupied 5% (Case 1) and 7% (Case 2) of the patient’s
remaining days. In Case 3, plaque radiotherapy was applied and
took only 4 days of treatment, representing 1% of the patient’s mean
remaining days. Including all three cases, systemic metastases
led to death at a mean of 10 months. Each form of radiotherapy
was successful in tumor control, avoiding pain, glaucoma, and
blindness, but this goal was most efficiently achieved with plaque
radiotherapy. Given the short life prognosis in such patients, we
advocate plaque radiotherapy for most rapid tumor control with
least time commitment.
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Precis
Plaque radiotherapy is a safe and effective treatment for iris
metastasis from esophageal carcinoma, with tumor control
achieved over 4 days of radiation exposure.
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